Webinar: Companion Diagnostics In Oncology
Executive Summary
Precision medicine and companion diagnostics are now core elements underlying the development of new oncology therapies, and they will certainly be major themes at the American Society of Clinical Oncology annual meeting set to kick off this week in Chicago. In advance of the ASCO confab, check out this webinar, coproduced by Medtech Insight and Pink Sheet, addressing technology and regulatory drivers for companion diagnostics and key clinical development considerations for pharma companies.
You may also be interested in...
Market Intel: Liquid Biopsy I – Analyzing Market Landmarks And Landmines
The worldwide liquid biopsy market is expected to reach $2.0bn by 2022, according to a new report by Meddevicetracker, "Oncology: Liquid Biopsy Products." The growth is driven by the rising global incidence of cancers, which, in turn, fuels innovation among companies to develop noninvasive diagnostic assays that obviate the need for tissue biopsy. This is the first in a two-part series providing an overview of the liquid biopsy market, as well as the technologies developed by the larger players in this space, and examining the biggest barriers and growth drivers. In the second part, we'll take a closer look at emerging companies in the sector and offer key insights from C-level attendees at the recent Liquid Biopsy Conference in San Francisco.
US FDA Raises Problems With EU Data Protection Reg, But Are They Among Those Misunderstanding It?
An FDA blog post says some inspections have been hindered and application assessments soon could be delayed by the EU General Data Protection Regulation (GDPR), but experts argue the law includes directions to allow data sharing and remain compliant.
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.